Table 2 Study population characteristics
From: Translation of oncology multidisciplinary team meeting (MDM) recommendations into clinical practice
Characteristic | Overall n = 835 | Gynae-onc n = 70 | Colorectal n = 87 | GU n = 63 | Skin n = 46 | Head&Neck n = 90 | Lung n = 143 | Breast n = 130 | Neuro-onc n = 89 | Upper GI n = 117 |
|---|---|---|---|---|---|---|---|---|---|---|
Median age (range) y | 65 (16–95) | 62 (17–88) | 64 (21–87) | 68 (31–85) | 67 (35–95) | 67 (24–98) | 70 (27–92) | 61 (38–94) | 53 (16–86) | 65 (31–90) |
Age group (%) | ||||||||||
 < 50 y | 148 (17.7) | 21 (30.0) | 15 (17.2) | 9 (14.3) | 2 (4.3) | 11 (12.2) | 7 (4.9) | 30 (23.1) | 31 (34.8) | 22 (18.8) |
 50–59 y | 149 (17.8) | 11 (15.7) | 20 (23.0) | 8 (12.7) | 3 (6.5) | 13 (14.4) | 17 (11.9) | 31 (23.8) | 25 (28.1) | 21 (17.9) |
 60–69 y | 241 (28.9) | 15 (21.4) | 26 (29.9) | 19 (30.2) | 19 (41.3) | 31 (34.4) | 47 (32.9) | 35 (26.9) | 16 (18.0) | 33 (28.2) |
 70–79 y | 194 (23.2) | 18 (25.7) | 16 (18.4) | 20 (31.7) | 9 (19.6) | 20 (22.2) | 47 (32.9) | 18 (13.8) | 15 (16.9) | 31 (26.5) |
 80+ y | 103 (12.3) | 5 (7.1) | 10 (11.5) | 7 (11.1) | 13 (28.3) | 15 (16.7) | 25 (17.5) | 16 (12.3) | 2 (2.2) | 10 (8.5) |
Gender (%) | ||||||||||
 Males | 429 (51.4) | 70 (100) | 41 (47.1) | 6 (9.5) | 14 (30.4) | 25 (27.8) | 53 (37.1) | 127 (97.7) | 45 (50.6) | 48 (41.0) |
 Females | 406 (48.6) | 0 (0) | 46 (52.9) | 57 (90.5) | 32 (69.6) | 65 (72.2) | 90 (62.9) | 3 (2.3) | 44 (49.4) | 69 (59.0) |
CALD status (%) | ||||||||||
 CALD, English | 161 (19.3) | 13 (18.6) | 15 (17.2) | 13 (20.6) | 5 (10.9) | 16 (17.8) | 22 (15.4) | 43 (33.1) | 15 (16.9) | 19 (16.2) |
 CALD, NESB | 210 (25.1) | 18 (25.7) | 21 (24.1) | 16 (25.4) | 3 (6.5) | 12 (13.3) | 38 (26.6) | 46 (35.4) | 25 (28.1) | 31 (26.5) |
 Non-CALD | 427 (51.1) | 37 (52.9) | 41 (47.1) | 25 (39.7) | 38 (82.6) | 62 (68.9) | 83 (58.0) | 41 (31.5) | 47 (52.8) | 53 (45.3) |
 Unknown | 37 (4.4) | 2 (2.9) | 10 (11.5) | 9 (14.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (2.2) | 14 (12.0) |
IRSD Quintiles (%) | ||||||||||
 1- Lowest SES | 195 (23.4) | 13 (18.6) | 23 (26.4) | 13 (20.6) | 7 (15.2) | 24 (26.7) | 34 (23.8) | 42 (32.3) | 20 (22.5) | 19 (16.4) |
 2 | 263 (31.5) | 28 (40.0) | 18 (20.7) | 16 (25.4) | 17 (37.0) | 29 (32.2) | 64 (44.8) | 19 (14.6) | 30 (33.7) | 42 (36.2) |
 3 | 237 (28.4) | 15 (21.4) | 29 (33.3) | 20 (31.7) | 14 (30.4) | 19 (21.1) | 24 (16.8) | 57 (43.8) | 24 (27.0) | 35 (30.2) |
 4 | 58 (7.0) | 3 (4.3) | 7 (8.0) | 9 (14.3) | 1 (2.2) | 7 (7.8) | 20 (14.0) | 2(1.5) | 2 (2.2) | 7 (6.0) |
 5 – Highest SES | 76 (9.1) | 10 (14.3) | 8 (9.2) | 4 (6.3) | 7 (15.2) | 11 (12.2) | 1 (0.7) | 9 (6.9) | 13 (14.6) | 13 (11.2) |
 Unknown | 5 (0.6) | 1 (1.4) | 2 (2.3) | 1 (1.6) | 0 (0) | 0 (0) | 0 (0) | 1(0.8) | 0 (0) | 0 (0) |
ECOG PS | ||||||||||
 0 | 265 (31.7) | 8 (11.4) | 25 (28.7) | 16 (25.4) | 24 (52.2) | 18 (20.0) | 61 (42.7) | 67 (51.5) | 27 (30.3) | 19 (16.2) |
 1 | 144 (17.2) | 2 (2.9) | 10 (11.5) | 4 (6.3) | 11 (23.9) | 7 (7.8) | 57 (39.9) | 19 (14.6) | 23 (25.8) | 11 (9.4) |
 2 | 48 (5.7) | 1 (1.4) | 1 (1.1) | 2 (3.2) | 3 (6.5) | 3 (3.3) | 19 (13.3) | 9 (6.9) | 6 (6.7) | 4 (3.4) |
 3 | 19 (2.3) | 0 (0) | 0 (0) | 1 (1.6) | 0 (0) | 0 (0) | 5 (3.5) | 4 (3.1) | 6 (6.7) | 3 (2.6) |
 4 | 4 (0.5) | 0 (0) | 1(1.1) | 0 (0) | 1 (2.2) | 1 (1.1) | 1 (0.7) | 0 (0) | 0 (0) | 0 (0) |
 Unknown | 355 (42.5) | 59 (84.3) | 50 (57.5) | 40 (63.5) | 7 15.2) | 61 (67.8) | 0 (0.0) | 31 (23.8) | 27 (30.3) | 80 (68.4) |
CCI (%) | ||||||||||
 0 | 403 (48.3) | 41 (58.6) | 57 (65.5) | 30 (47.6) | 17 (37.0) | 33 (36.7) | 29 (20.3) | 74 (56.9) | 61 (68.5) | 61 (52.1) |
 1 to 2 | 324 (38.8) | 26 (37.1) | 27 (31.0) | 24 (38.1) | 20 (43.5) | 40 (44.4) | 80 (55.9) | 42 (32.3) | 22 (24.7) | 43 (36.8) |
 3+ | 102 (12.2) | 3 (4.3) | 2 (2.3) | 7 (11.1) | 9 (19.5) | 14 (15.6) | 34 (23.8) | 14 (10.8) | 6 (6.8) | 13 (11.1) |
 Unknown | 6 (0.7) | 0 (0) | 1 (1.2) | 2 (3.2) | 0 (0) | 3 (3.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Presentation by tumour type (%) | ||||||||||
 MDM specific tumour | 737 (88.3) | 53 (75.7) | 84 (96.6) | 51 (81.0) | 46 (100.0) | 79 (87.8) | 127 (88.8) | 130 (100) | 84(94.4) | 83 (70.9) |
 Other cancer | 49 (5.9) | 4 (5.7) | 0 (0) | 6 (9.5) | 0 (0) | 5 (5.6) | 7 (4.9) | 0 (0) | 5 (5.6) | 22 (18.8) |
 Non-cancer | 33 (4.0) | 13 (18.6) | 3 (3.4) | 2 (3.2) | 0 (0) | 6 (6.7) | 0 (0.0) | 0 (0) | 0 (0) | 9 (7.7) |
 Unknown | 16 (1.9) | 0 (0) | 0 (0) | 4 (6.3) | 0 (0) | 0 (0) | 9 (6.3) | 0 (0) | 0 (0) | 3 (2.6) |
Stage (%) | ||||||||||
 0–3 | 373 (44.7) | 34 (48.6) | 40 (46.0) | 13 (20.6) | 36 (78.3) | 29 (32.2) | 87 (60.8) | 111 (85.4) | 0 (0.0) | 23 (19.7) |
 4/ Malignant CNS | 237 (28.4) | 7 (10.0) | 20 (23.0) | 11 (17.5) | 9 (19.6) | 41 (45.6) | 46 (32.2) | 14 (10.8) | 57 (64.1) | 32 (27.4) |
 Benign | 26 (3.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 26 (29.2) | 0 (0) |
 Unknown | 199 (23.8) | 29 (41.4) | 27 (31.0) | 39 (61.9) | 1 (2.2) | 20 (22.2) | 10 (7.0) | 5 (3.8) | 6 (6.7) | 62 (53.0) |
Reason first MDM presentation (%) | ||||||||||
 First diagnosis | 591 (70.8) | 60 (85.7) | 53 (60.9) | 37 (58.7) | 39 (84.8) | 62 (68.9) | 106 (74.1) | 103 (79.2) | 50 (56.2) | 81 (69.2) |
 Recurrence | 142 (17.0) | 7 (10.0) | 11 (12.6) | 13 (20.6) | 6(13.0) | 26(28.9) | 24 (16.8) | 7 (5.4) | 34 (38.2) | 14 (12.0) |
 On Treatment | 93 (11.1) | 3 (4.3) | 21 (24.1) | 12 (19.0) | 1 (2.2) | 0 (0) | 13 (9.1) | 18 (13.9) | 3 (3.4) | 22 (18.8) |
 Other | 9 (1.1) | 0 (0) | 2 (2.3) | 1 (1.6) | 0 (0) | 2 (2.2) | 0 (0) | 2 (1.5) | 2 (2.2) | 0 (0) |
No of MDMs (%) | ||||||||||
 1 | 643 (77) | 39 (55.7) | 68 (78.2) | 58 (92.1 | 39 (84.8) | 65 (72.2) | 110 (76.9) | 108 (83.1) | 69 (77.5) | 87 (74.4) |
 2 | 166 (19.9) | 25 (35.7) | 16 (18.4) | 5 (7.9) | 7 (15.2) | 24 (26.7) | 30 (21) | 19 (14.6) | 17 (19.1) | 23 (19.7) |
 3–4 | 26 (3.1) | 6 (8.6) | 3 (3.4) | 0 (0) | 0 (0) | 1 (1.1) | 3 (2.1) | 3 (2.3) | 3 (3.4) | 7 (5.9) |
Overall MDM Consensus (%) | ||||||||||
 Treatment | 611 (73.2) | 55 (78.6) | 68 (78.2) | 35 (55.6) | 32 (69.6) | 70 (77.8) | 108 (75.5) | 116 (89.2) | 36 (40.4) | 91 (77.8) |
 No treatment/ clinical follow-up | 181 (21.7) | 15 (21.4) | 12 (13.8) | 21 (33.3) | 14 (30.4) | 18 (20) | 25 (17.5) | 12 (9.2) | 47 (52.8) | 17 (14.6) |
 Other | 43 (5.1) | 0 (0) | 7 (8) | 7 (11.1) | 0 (0) | 2 (2.2) | 10 (7) | 2 (1.5) | 6 (6.7) | 9 (7.7) |
Overall Intent | ||||||||||
 Curative | 619 (74.1) | 58 (82.9) | 59 (67.8) | 48 (76.2) | 39 (84.8) | 72 (80) | 73 (51) | 117 (90) | 70 (78.7) | 83 (70.9) |
 Palliative | 203 (24.3) | 12 (17.1) | 28 (32.2) | 15 (23.8) | 7 (15.2) | 18 (20) | 57 (39.9) | 13 (10) | 19 (21.3) | 34 (29.1) |
 Unknown | 13 (1.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 13 (9.1) | 0 (0) | 0 (0) | 0 (0) |